{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["Neoplasm Metastasis","Liver Metastases","Colorectal Cancer","Colorectal Neoplasms","Liver Neoplasms"],"disease":["Neoplasm Metastasis","Liver Metastases","Colorectal Cancer","Colorectal Neoplasms","Liver Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2137916"],"location":["China"],"study_start_month":["9"],"keyword":["Objective response rate","Conversion therapy","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Not provided"],"additional_accession":[]},"is_claimable":false,"name":"Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer","description":"A multi-center, non-random, open study ,to observe efficacy and safety of bevacizumab plus Oxaliplatin based multidrug chemotherapy as conversion therapy for patients with previously untreated unresectable liver metastases from colorectal cancer.","dates":{"creation":"2012-09-15"},"accession":"2137916","cross_references":{"ClinicalTrials___gov":["NCT01763450"]}}